With regard to SoHO preparations that pose a risk that is more than negligible, and the benefit is expected to outweigh that risk, the applicant should propose a plan for clinical-outcome monitoring that should fulfil different requirements appropriate to the risk in question. The most up-to-date guidance of the European Directorate for the Quality of Medicines & HealthCare (EDQM), which is a Directorate of the Council of Europe, should be considered relevant in the design of clinical follow-up plans proportionate in extent and complexity to the identified level of risk of the SoHO preparation. In the case of low risk and a positive benefit-risk assessment, in addition to the mandatory continuous vigilance reporting, the applicant should organise proactive clinical follow-up for a defined number of SoHO recipients. For moderate risk and a positive benefit-risk assessment, in addition to the mandatory vigilance reporting and the clinical follow-up, the applicant should propose a SoHO clinical study with monitoring of pre-defined clinical end-points. In the case of high risk and a positive benefit-risk assessment, and cases where the risk or the benefit are not evaluable due to a lack of scientific and clinical data or knowledge, SoHO clinical studies should include a comparison with a standard therapy, ideally in a study with SoHO recipients allocated to test and control groups in a randomised manner. The SoHO competent authority should approve the plans before they are implemented and should assess the outcome data as part of a SoHO preparation authorisation. In SoHO clinical studies, patients’ rights, safety, dignity and well-being should always be the priority and the SoHO clinical study should be designed in a way that leads to reliable and robust data and conclusions.
Recital 45, Regulation (EU) 2024/1938
In force